Beranda › Penyakit Graft-versus-Host › Pennsylvania
Uji klinis Penyakit Graft-versus-Host di Pennsylvania
6 studi untuk Penyakit Graft-versus-Host mencari peserta di lokasi di Pennsylvania.
Kota di Pennsylvania
Teks studi resmi (Bahasa Inggris)
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
- UMPC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07565220A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 2
Usia 2 ke atas · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT04710576A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
- University of Pittsburgh Medical Center (Data Collection Only), Pittsburgh
Menerima pesertaFase 2
Usia 4 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT05675930A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Pennsylvania, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT06615050Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
- Penn State Cancer Institute, Hershey
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Apr 2026 · NCT06926595A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Des 2025 · NCT06619561Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.